Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Differentiation syndrome associated with enasidenib (AG-221), a selective inhibitor of mutant isocitrate dehydro-genase 2 (mIDH2)
    Meeting Abstract

    Fathi, A. T.; DiNardo, C. D.; Kline, I.; Kenvin, L.; Gupta, I.; Attar, E. C.; Stein, E. M.; de Botton, S.
    Haematologica (2017)

    Fulltext@MSK | Save
  • Enasidenib (AG-221) in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase 1 dose-escalation and expansion study
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Pollyea, D. A.; Fathi, A. T.; Roboz, G. J.; Altman, J. K.; Stone, R. M.; Flinn, I. W.; Kantarjian, H. M.; Collins, R.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Vadastuximab talirine plus hypomethylating agents: A well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia
    Meeting Abstract

    Ravandi, F.; Stein, A.; Erba, H.; Lancet, J.; Stein, E.; Faderl, S.; Walter, R.; Advani, A.; DeAngelo, D.; Kovacsovics, T.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2- and TET2-mutant acute myeloid leukemia
    Journal Article

    Shih, A. H.; Meydan, C.; Shank, K.; Garrett-Bakelman, F. E.; Ward, P. S.; Intlekofer, A. M.; Nazir, A.; Stein, E. M.; Knapp, K.; Glass, J.; more...
    Cancer Discovery (2017)

    Fulltext@MSK | Save
  • Targeting IDH mutations in acute myeloid leukemia
    Meeting Abstract

    Tallman, M. S.; Stein, E. M.; Coombs, C. C.; Levine, R. L.
    Annals of Hematology (2017)

    Fulltext@MSK | Save
  • Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias
    Journal Article

    Wang, K.; Sanchez-Martin, M.; Wang, X.; Knapp, K. M.; Koche, R.; Vu, L.; Nahas, M. K.; He, J.; Hadler, M.; Stein, E. M.; more...
    Leukemia (2017)

    Fulltext@MSK | Save
  • Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS)
    Meeting Abstract

    Stein, E. M.; Fathi, A. T.; DiNardo, C. D.; Pollyea, D. A.; Swords, R. T.; Roboz, G. J.; Collins, R.; Sekeres, M. A.; Stone, R. M.; Attar, E. C.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Vadastuximab talirine plus hypomethylating agents: A well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia (AML)
    Meeting Abstract

    Fathi, A. T.; Erba, H. P.; Lancet, J. E.; Stein, E. M.; Ravandi, F.; Faderl, S.; Walter, R. B.; Advani, A.; DeAngelo, D. J.; Kovacsovics, T. J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of mutant IDH1
    Meeting Abstract

    DiNardo, C. D.; de Botton, S.; Stein, E. M.; Roboz, G. J.; Swords, R. T.; Pollyea, D. A.; Fathi, A. T.; Collins, R.; Altman, J. K.; Flinn, I. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML)
    Meeting Abstract

    Bixby, D. L.; Stein, A. S.; Fathi, A. T.; Kovacsovics, T. J.; Levy, M. Y.; Erba, H. P.; Lancet, J. E.; Jillella, A. P.; Ravandi, F.; Walter, R. B.; more...
    Blood (2016)

    Fulltext@MSK | Save